On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
"I think all disciplines go through a process, a journey of being imagined and then becoming a science and then becoming a discipline of...
What makes India a smart and viable setting for today’s clinical trials? Join us for the latest episode of Few & Far Between. Biorasi's ...
"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will...